Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3108693)

Published in Drug Healthc Patient Saf on May 24, 2010


Adie Viljoen1, Anthony S Wierzbicki

Author Affiliations

1: Lister Hospital, Stevenage, Hertfordshire, UK;

Associated clinical trials:

Niacin Plus Statin to Prevent Vascular Events | NCT00120289

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630

Articles cited by this

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 44.03

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41

Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78

Standards of medical care in diabetes--2008. Diabetes Care (2008) 17.23

Atherosclerosis. Nature (2000) 15.95

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79

Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35

Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J (2007) 5.92

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 5.82

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 5.51

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest (2007) 5.38

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA (2009) 4.42

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16

Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys (1955) 3.63

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49

Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39

Clinical practice. Hypertriglyceridemia. N Engl J Med (2007) 3.28

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05

Beneficial cardiovascular pleiotropic effects of statins. Circulation (2004) 2.89

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86

Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem (2001) 2.81

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol (2005) 2.67

Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol (2004) 2.50

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol (2000) 2.21

HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation (1991) 1.94

The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol (2005) 1.88

Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin (1956) 1.80

High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis (1988) 1.79

Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation (2000) 1.76

Statin-related adverse events: a meta-analysis. Clin Ther (2006) 1.71

NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther (2007) 1.67

Laboratory assessment of HDL heterogeneity and function. Clin Chem (2008) 1.67

Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol (2004) 1.61

Mechanism of action of niacin. Am J Cardiol (2008) 1.55

Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics (2005) 1.44

Low-density lipoprotein size and cardiovascular risk assessment. QJM (2006) 1.40

The value of a specialist lipid clinic. Int J Clin Pract (2008) 1.40

Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol (1997) 1.30

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28

Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care (1998) 1.28

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract (2008) 1.27

Triglycerides and risk for coronary heart disease. JAMA (2007) 1.27

Comparison of statins in hypertriglyceridemia. Am J Cardiol (1998) 1.23

Update on dyslipidemia. J Clin Endocrinol Metab (2007) 1.22

Lp(a) lipoprotein redux--from curious molecule to causal risk factor. N Engl J Med (2009) 1.19

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis (2007) 1.13

Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol (2006) 1.09

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol (2007) 1.07

Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice. J Am Board Fam Pract (2004) 1.01

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol (2009) 0.98

Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest (2005) 0.96

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem (2007) 0.95

An uncertain future for cardiovascular drug development? N Engl J Med (2009) 0.95

Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract (2008) 0.93

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1998) 0.93

The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract (2009) 0.92

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract (2004) 0.92

New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Pat Cardiovasc Drug Discov (2008) 0.92

High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis (2003) 0.90

Potential options to treat hypertriglyceridaemia. Curr Drug Targets (2009) 0.87

Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther (2007) 0.87

Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol (2004) 0.86

The HALTS trial--halting atherosclerosis or halted too early? N Engl J Med (2009) 0.86


Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep (2005) 0.83

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs (2009) 0.83

The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol (2007) 0.83

Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology (2009) 0.82

Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis. World J Gastroenterol (2003) 0.82

Effects of inflammation on high-density lipoproteins. Arterioscler Thromb Vasc Biol (2002) 0.81

Life after statin patent expiries. Nat Rev Drug Discov (2006) 0.80

Niacin: an old drug rejuvenated. Curr Atheroscler Rep (2009) 0.80

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol (2002) 0.80

Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos (2007) 0.80

Gender-related differences in electrocardiographic parameters and their association with cardiac events in patients after myocardial infarction. Am J Cardiol (2008) 0.80

Influence of oxygen inhalation on cholesterol metabolism. Arch Biochem Biophys (1954) 0.79

Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract (2008) 0.76

Resurrecting an old drug--a flash in the pan or here to stay? Int J Clin Pract (2009) 0.76

Articles by these authors

(truncated to the top 100)

Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A (2004) 1.72

Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl) (2005) 1.56

Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin (2012) 1.52

Getting better value from the NHS drug budget. BMJ (2010) 1.47

Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39

Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem (2005) 1.27

Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab (2004) 1.21

Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet (2003) 1.17

The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism. Genome Res (2012) 1.14

Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk (2002) 1.13

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation (2015) 1.13

Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol (2003) 1.10

Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage. FEBS J (2008) 1.05

Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin (2004) 1.05

Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00

Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension (2007) 1.00

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev (2007) 0.97

Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Curr Med Res Opin (2004) 0.95

Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol (2010) 0.94

Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet Gynecol (2006) 0.93

Spinning stars: ASTEROID's impact on atherosclerosis. Lancet (2006) 0.93

Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther (2012) 0.92

Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal alpha oxidation of phytanic acid. Chem Biol (2002) 0.92

Lipoprotein a: where are we now? Curr Opin Cardiol (2009) 0.92

Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. Curr Med Res Opin (2003) 0.91

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90

Identification of PEX7 as the second gene involved in Refsum disease. Adv Exp Med Biol (2003) 0.88

The chemical biology of branched-chain lipid metabolism. Prog Lipid Res (2003) 0.87

Potential options to treat hypertriglyceridaemia. Curr Drug Targets (2009) 0.87

Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy. Surv Ophthalmol (2010) 0.86

The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther (2011) 0.86

Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis. Cytokine (2009) 0.86

The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin (2010) 0.85

New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des (2011) 0.85

A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One (2013) 0.83

Simple sequence-specific-primer-PCR method to identify the three main apolipoprotein E haplotypes. Clin Chem (2003) 0.83

A review of the lipid-related effects of fluvastatin. Curr Med Res Opin (2005) 0.82

The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry (2010) 0.82

The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin (2002) 0.81

Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant (2004) 0.81

Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens (2006) 0.81

Statins and noncardiac vascular disease. Curr Opin Cardiol (2012) 0.81

The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res (2002) 0.80

Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. J Nephrol (2003) 0.80

Images in clinical medicine. Lipemia retinalis. N Engl J Med (2005) 0.80

Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. Int J Cardiol (2003) 0.80

Copper:caeruloplasmin ratio. J Clin Pathol (2007) 0.79

CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. J Lipid Res (2013) 0.79

Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin (2005) 0.79

NO problem: arterial and venous endothelial function and erectile dysfunction. Eur Urol (2011) 0.78

Ideal lipid profile and genes for an extended life span. Curr Opin Cardiol (2011) 0.78

Erectile dysfunction and coronary heart disease. Curr Opin Cardiol (2015) 0.78

Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. Curr Pharm Des (2010) 0.77

Clinical significance of oxidation from phytol to phytanic acid in man. Mol Genet Metab (2004) 0.77

Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther (2012) 0.77

Cardiovascular risk assessment. Lancet (2005) 0.77

Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol (2011) 0.77

Lipid-lowering agents. J Cardiovasc Pharmacol Ther (2013) 0.77

Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. Eur J Endocrinol (2006) 0.77

Percentage non-caeruloplasmin bound copper. Clin Biochem (2007) 0.76

Shape of the Nations survey and attitudes to cardiometabolic risk. Curr Med Res Opin (2007) 0.76

Very low plasma copper levels do not automatically imply severe copper deficiency. Ann Clin Biochem (2005) 0.76

PCI and stable coronary heart disease--COURAGE to change our minds? Curr Vasc Pharmacol (2007) 0.76

Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2002) 0.76

Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care (2004) 0.76

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb (2014) 0.76

Cost utility of prenatal diagnosis. Lancet (2004) 0.75

Epidemiological studies are meaningless without proof of long-term data stability. Am J Med (2008) 0.75

More on PROSPER. Lancet (2003) 0.75

Screening for cardiovascular disease. Eur Heart J (2004) 0.75

Accuracy of cardiovascular risk estimation. Clin Chem (2003) 0.75

Use of coronary calcification scores to predict coronary heart disease. JAMA (2004) 0.75

Primary and secondary prevention in obesity. Int J Clin Pract (2007) 0.75

Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. Int J Clin Pract (2013) 0.75

Letter regarding article by Gazzaruso et al, "Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated, type 2 diabetic patients". Circulation (2005) 0.75

Targets--who needs them? Success with statin therapies. Int J Clin Pract (2007) 0.75

Role of phytanoyl-CoA 2-hydroxylase in phytanic acid metabolism. Adv Exp Med Biol (2003) 0.75

Treatment-to-target for lipids in primary care. Int J Clin Pract (2003) 0.75

Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. Curr Med Res Opin (2013) 0.75

Dyslipidaemia: Failure to THRIVE: the end for niacin? Nat Rev Cardiol (2013) 0.75

Raising HDL-C: back to the future? Int J Clin Pract (2007) 0.75

Raising high-density lipoprotein. Int J Clin Pract (2004) 0.75

Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol. Curr Opin Lipidol (2007) 0.75

Genetics and molecular biology: genetic epidemiology. Curr Opin Lipidol (2004) 0.75

Radiotherapy, chemotherapy and atherosclerosis. Curr Opin Cardiol (2017) 0.75

Prioritizing health outcomes in a limited world: writing lipid guidelines. Curr Opin Lipidol (2015) 0.75

Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Rev Pharmacoecon Outcomes Res (2009) 0.75

Low HDL-cholesterol: Common and under-treated, but which drug to use? Int J Clin Pract (2006) 0.75

Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart (2012) 0.75

Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing story. Int J Clin Pract (2007) 0.75

How aggressively should cholesterol targets be pursued? Br J Hosp Med (Lond) (2007) 0.75

Secondary tests for stratification of risk for atherosclerosis. Curr Med Res Opin (2013) 0.75

HDL: who needs it? Int J Clin Pract (2011) 0.75

The need for combination drug therapies in patients with complex dyslipidemia. Curr Cardiol Rep (2013) 0.75

METEOR: aiming at the stars for asymptomatic carotid artery atherosclerosis? Int J Clin Pract (2007) 0.75

Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. J Trace Elem Med Biol (2008) 0.75

Towards companion diagnostics for the management of statin therapy. Expert Opin Med Diagn (2009) 0.75

Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol (2014) 0.75

Lipidomics in diabetes. Curr Opin Endocrinol Diabetes Obes (2022) 0.75